<DOC>
	<DOC>NCT02419391</DOC>
	<brief_summary>A total of 63 subjects will be recruited into three groups (18 subjects per group will receive MVA BN RSV vaccine and three subjects per group will receive placebo). Liquid frozen suspension of MVA BN RSV. Each subject will receive two vaccinations with either MVA-BN RSV vaccine 1 x 108 TCID50 per 0.5 ml, 1 x 107 TCID50 per 0.5 ml or with placebo.</brief_summary>
	<brief_title>Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>signed and dated an informed consent form Body mass index ≥ 18.5 and &lt; 35. Women of childbearing potential (WOCBP) must have used an acceptable method of contraception Pregnant or breastfeeding women. Uncontrolled serious infection, i.e. not responding to antimicrobial therapy. History of any serious medical condition. History of or active autoimmune disease. Known or suspected impairment of immunologic functions.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>RSV Vaccines</keyword>
	<keyword>Respiratory Syncytial Virus Vaccines</keyword>
</DOC>